Nihira S - Search Results

1

Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.

Masuda N, Matsui K, Yamamoto N, Nogami T, Nakagawa K, Negoro S, Takeda K, Takifuji N, Yamada M, Kudoh S, Okuda T, Nemoto S, Ogawa K, Myobudani H, Nihira S, Fukuoka M. Masuda N, et al. Among authors: nihira s. Clin Cancer Res. 2000 Jun;6(6):2288-94. Clin Cancer Res. 2000. PMID: 10873079 Clinical Trial.

2

Guidelines for clinical evaluation of anti-cancer drugs.

Minami H, Kiyota N, Kimbara S, Ando Y, Shimokata T, Ohtsu A, Fuse N, Kuboki Y, Shimizu T, Yamamoto N, Nishio K, Kawakami Y, Nihira SI, Sase K, Nonaka T, Takahashi H, Komori Y, Kiyohara K. Minami H, et al. Among authors: nihira si. Cancer Sci. 2021 Jul;112(7):2563-2577. doi: 10.1111/cas.14967. Epub 2021 Jun 8. Cancer Sci. 2021. PMID: 33990993 Free PMC article.

3

[Development of HER2-specific humanized antibody Herceptin (trastuzumab)].

Nihira S. Nihira S. Nihon Yakurigaku Zasshi. 2003 Dec;122(6):504-14. doi: 10.1254/fpj.122.504. Nihon Yakurigaku Zasshi. 2003. PMID: 14639005 Review. Japanese.

4

Anti-angiogenic therapy against gastrointestinal tract cancers.

Iwasaki J, Nihira S. Iwasaki J, et al. Among authors: nihira s. Jpn J Clin Oncol. 2009 Sep;39(9):543-51. doi: 10.1093/jjco/hyp062. Epub 2009 Jun 16. Jpn J Clin Oncol. 2009. PMID: 19531544 Review.

5

The ¹³⁷Cs activity concentration of suspended and dissolved fractions in irrigation waters collected from the 80 km zone around TEPCO's Fukushima Daiichi Nuclear Power Station.

Tsukada H, Nihira S, Watanabe T, Takeda S. Tsukada H, et al. Among authors: nihira s. J Environ Radioact. 2017 Nov;178-179:354-359. doi: 10.1016/j.jenvrad.2017.08.002. Epub 2017 Aug 12. J Environ Radioact. 2017. PMID: 28807451

6

Application of homogeneous time-resolved fluorescence (HTRFTM) to monitor poly-ubiquitination of wild-type p53.

Yabuki N, Watanabe S, Kudoh T, Nihira Si, Miyamato C. Yabuki N, et al. Among authors: nihira si. Comb Chem High Throughput Screen. 1999 Oct;2(5):279-87. Comb Chem High Throughput Screen. 1999. PMID: 10539989

7

Screening of an inhibitor of the tetracycline efflux pump in a tetracycline-resistant clinical-isolate of Staphylococcus aureus 743.

Hirata T, Wakatabe R, Nielsen J, Satoh T, Nihira S, Yamaguchi A. Hirata T, et al. Among authors: nihira s. Biol Pharm Bull. 1998 Jul;21(7):678-81. doi: 10.1248/bpb.21.678. Biol Pharm Bull. 1998. PMID: 9703248 Free article.

8

[Immune intervention by peptides having a MHC class II binding motif--application of MHC blockers to autoimmune disease models].

Nihira S. Nihira S. Nihon Rinsho. 1997 Jun;55(6):1525-30. Nihon Rinsho. 1997. PMID: 9200943 Review. Japanese.

9

Induction of class II major histocompatibility complex blockade as well as T cell tolerance by peptides administered in soluble form.

Nihira SI, Falcioni F, Juretic A, Bolin D, Nagy ZA. Nihira SI, et al. Eur J Immunol. 1996 Aug;26(8):1736-42. doi: 10.1002/eji.1830260811. Eur J Immunol. 1996. PMID: 8765014

10

Relationship of urinary sodium and potassium and of urinary sodium/creatinine, potassium/creatinine and sodium/potassium ratios to stomach cancer and cerebrovascular disease mortalities in Japanese women.

Takemori K, Mikami S, Nihira S, Sasaki N. Takemori K, et al. Among authors: nihira s. Tohoku J Exp Med. 1993 Nov;171(3):185-94. doi: 10.1620/tjem.171.185. Tohoku J Exp Med. 1993. PMID: 8160175 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters